title: A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.
abstract: OBJECTIVE
  Fentanyl is a synthetic opioid commonly used as an anesthetic and also increasingly popular as a sedative agent in neonates. Initial dosage regimens in this population are often empirically derived from adults on a body weight basis. However, ontogenic maturation processes related to drug disposition are not necessarily always body weight correlates. We developed a predictive pharmacokinetic/pharmacodynamic model that includes growth and maturation physiologic changes for fentanyl in neonatal care.
  
  
  METHODS
  Key pharmacokinetic variables and principles (protein binding, clearance, distribution) as related to fentanyl pharmacokinetic/pharmacodynamic behavior in adults (tricompartmental model) and to neonatal physiologic data (organ weights and blood flows, body composition, renal and hepatic function, etc.) were used to guide the building of a semi-physiologic ontogenic model. The model applies to a normal-term neonate without any other intervention. Then, extension to a pharmacokinetic/pharmacodynamic link model for fentanyl was made. The final model was evaluated by predicting the time course of plasma concentrations and the effect of a standard regimen of 10.5 μg/kg over a 1-h period followed by 1.5 μg/kg/h for 48 h.
  
  
  RESULTS
  Hepatic clearance was linked to ontogeny of unbound fraction and of α1-acid glycoprotein. All parameters were reduced in the neonate compared to adults but in a differing proportion due to qualitative changes in physiology that are analyzed and accounted for. Systemic clearance (CLS), volume of the central compartment (V1) and steady-state volume of distribution predicted by the model were 0.028 L/min, 1.26 L, and 22.04 L, respectively. Weight-corrected parameters generally decreased in adults compared with neonates, but differentially, e.g., CLS = 0.0093 versus 0.0088 L/min/kg, while V1 = 0.42 versus 0.18 L/kg (neonates vs. adults). Under such complexity a pharmacokinetic/pharmacodynamic model is the appropriate method for rational efficacy targeting. Fentanyl pharmacodynamics in neonates were considered to be similar to those in adults except for the equilibrium rate constant, which was also scaled on an ontogenic basis. The model adequately predicted the reported mean expected concentration-time profiles for the standard regimen.
  
  
  CONCLUSIONS
  Integrated pharmacokinetic/pharmacodynamic modeling showed that the usually prescribed dosage regimens of fentanyl in neonates may not always provide the optimum degree of sedation. The model could be used in optimal design of clinical trials for this vulnerable population. Prospective clinical testing is the reasonable next step.
authors: Department of Pharmacology, School of Medicine, University of the Basque Country, Leioa, Spain.
authors: Esther
authors: E
authors: Encinas
authors: Rosario
authors: R
authors: Calvo
authors: John C
authors: JC
authors: Lukas
authors: Valvanera
authors: V
authors: Vozmediano
authors: Monica
authors: M
authors: Rodriguez
authors: Elena
authors: E
authors: Suarez
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001835:Body Weight; D005283:Fentanyl / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D006128:Growth / Q000502:physiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D007231:Infant, Newborn / Q000502:physiology; D008954:Models, Biological; D059408:Pain Management
chemical_list: D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives; D005283:Fentanyl
references: Paediatr Anaesth. 2011 Mar;21(3):214-21
references: 21244569
references: Can J Anaesth. 1987 Mar;34(2):152-5
references: 3829301
references: J Pediatr. 2000 Jun;136(6):767-70
references: 10839874
references: Clin Ther. 2005 Jun;27(6):877-99
references: 16117990
references: Crit Care Med. 1996 Sep;24(9):1473-81
references: 8797618
references: Am J Physiol. 1989 Apr;256(4 Pt 2):R1005-10
references: 2705568
references: Br J Clin Pharmacol. 2005 Jun;59(6):691-704
references: 15948934
references: AAPS PharmSci. 2002;4(1):E4
references: 12049488
references: Clin Pharmacokinet. 2006;45(10):1013-34
references: 16984214
references: Anesthesiology. 1988 Nov;69(5):683-7
references: 3189915
references: Clin Pharmacokinet. 2006;45(7):683-704
references: 16802850
references: Clin Pharmacokinet. 2008;47(4):231-43
references: 18336053
references: Br J Clin Pharmacol. 2003 Nov;56(5):489-93
references: 14651721
references: Intensive Care Med. 2006 Aug;32(8):1125-36
references: 16699772
references: AAPS PharmSci. 2000;2(1):E3
references: 11741219
references: Drug Metab Dispos. 1997 Sep;25(9):1072-80
references: 9311623
references: Clin Pharmacokinet. 2006;45(9):931-56
references: 16928154
references: Clin Pharmacokinet. 2002;41(12):959-98
references: 12222995
references: Clin Pharmacokinet. 1999 Dec;37(6):485-505
references: 10628899
references: J Pharmacol Exp Ther. 1987 Jan;240(1):159-66
references: 3100765
references: Paediatr Drugs. 1999 Apr-Jun;1(2):109-26
references: 10937446
references: J Pharmacol Exp Ther. 2005 Jun;313(3):1136-49
references: 15701707
references: J Perinatol. 1997 Mar-Apr;17(2):135-9
references: 9134513
references: Br J Anaesth. 1996 Mar;76(3):365-8
references: 8785135
references: Anesthesiology. 1985 Mar;62(3):234-41
references: 3919613
references: Nat Rev Drug Discov. 2007 Feb;6(2):140-8
references: 17268485
references: Anesth Analg. 1986 Mar;65(3):227-32
references: 3954090
references: Clin Pharmacokinet. 2013 Jan;52(1):23-36
references: 23100195
references: Anesthesiology. 1991 Jan;74(1):34-42
references: 1670913
references: J Pharmacol Exp Ther. 2006 Nov;319(2):682-92
references: 16855177
references: Eur J Clin Pharmacol. 2011 May;67 Suppl 1:75-86
references: 21246352
references: Br J Clin Pharmacol. 1985 Nov;20(5):500-2
references: 4074621
references: Clin Pharmacokinet. 1996 Dec;31(6):423-43
references: 8968656
references: Clin Pharmacol Ther. 1992 Mar;51(3):334-42
references: 1544290
references: J Pharmacol Exp Ther. 2007 Oct;323(1):346-55
references: 17646430
references: Dev Pharmacol Ther. 1991;17(3-4):121-7
references: 1841826
references: Clin Pharmacokinet. 2002;41(13):1077-94
references: 12403644
references: Anesthesiology. 1992 Mar;76(3):334-41
references: 1539843
references: Anesth Analg. 1984 Jun;63(6):577-82
references: 6731878
references: Paediatr Anaesth. 2010 Mar;20(3):223-32
references: 19627530
references: Best Pract Res Clin Anaesthesiol. 2010 Sep;24(3):419-31
references: 21033017
references: Int J Pharm. 2011 Aug 30;415(1-2):9-14
references: 21376791
references: Clin Pharmacokinet. 2006;45(1):1-11
references: 16430308
references: Drug Metab Pharmacokinet. 2009;24(1):25-36
references: 19252334
references: Paediatr Anaesth. 2007 Nov;17(11):1028-34
references: 17897267
references: Anesth Analg. 1982 Dec;61(12):968-71
references: 7149300
references: J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):25-40
references: 21046208
references: Fundam Clin Pharmacol. 2008 Dec;22(6):579-87
references: 19049658
references: Drug Metab Dispos. 1996 Sep;24(9):932-9
references: 8886601
references: Anesthesiology. 2002 Dec;97(6):1393-400
references: 12459664
references: J Clin Pharmacol. 2001 Jul;41(7):757-63
references: 11452708
references: Anesthesiology. 1991 Jan;74(1):53-63
references: 1824743